Page 3 - Serum Institute Of India

Biocon IPO after integration of Viatris market: MD & CEO Shreehas Tambe

'From our perspective, we have operated with a high band and a lower band model'

Serum Institute of India doubles Biocon investment to $300 million

The earlier investment by SILS in BBL was at a valuation of $4.9 billion, and the fresh $150-million investment pushes it up at $6 billion

Serum Institute to double its investment in Biocon's unit to $300 million

SILS will now make an additional equity investment of $150 million through the conversion of an earlier loan provided to Biocon Pharma into equity in BBL

Current Covid variants mild, senior citizens can take booster dose: SII CEO

He further stated that Covovax is also being provided in the United States of America and Europe

Current Covid-19 strain mild, SII produced 5-6 mn Covovax doses: Poonawalla

The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla on Saturday. Poonawalla was talking to media persons amid rising cases of coronavirus infections in the country since March. India has recorded 12,193 fresh COVID-19 cases in a span of 24 hours, with the number of active cases of the infection going up to 67,556, the Union health ministry said on Saturday. Currently, the COVID strain is not severe, it's just a mild strain. Just for precautionary measures, elderly people can get the booster dose, but it would be their choice whether or not to take it. Five to six million doses of Covovax are available. We will also produce the same amount of Covishield doses in the next two to three months, said Poonawalla. As per a health bulletin of the Maharashtra government on Friday, the XBB.1.16 variant of Omicron is currently the domina

Oxford, Serum Institute deliver malaria vax; Ghana first to give nod

The approval is unusual as it comes before the publication of final-stage trial data

Ghana becomes first country to approve Oxford malaria vaccine for children

It is hoped that this crucial step will enable the vaccine to help Ghanaian and African children to effectively combat malaria, said Oxford University

Oxford University, SII tie-up delivers 'high efficacy' malaria vaccine

A University of Oxford developed and Serum Institute of India (SII) manufactured and scaled up "high efficacy" malaria vaccine has been licensed for use in Ghana by Africa's Food and Drugs Authority, the university announced here on Thursday. The R21/Matrix-M vaccine, leveraging Novavax's adjuvant technology, has been approved for use in children aged 5 to 36 months the age group at the highest risk of death from malaria. It marks the first regulatory clearance for the R21/Matrix-M malaria vaccine for use in any country. This marks a culmination of 30 years of malaria vaccine research at Oxford with the design and provision of a high efficacy vaccine that can be supplied at adequate scale to the countries who need it most, said Professor Adrian Hill, Chief investigator of the programme and Director of the Oxford University's Jenner Institute at the Nuffield Department of Medicine. As with the Oxford-AstraZeneca COVID-19 vaccine, our partnership with the Serum Institute of India has

Serum re-starts Covishield production, seeks to despatch 6 mn Covovax doses

Initiates talks with private hospitals for dispatching existing Covovax stock; Conducts in-vitro studies on human blood samples for neutralising antibody titres against XBB in India

Covid-19: Serum Institute of India restarts manufacturing Covishield

Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the company already has six million booster doses of Covovax vaccine available and adults must take the booster shot. Reacting to reports of COVID-19 vaccines shortage, he said manufacturers are ready but there has been no demand. "Just as a precaution, at risk we have done it so that people have a Covishield as a choice if they want it," Poonawalla told PTI on restarting of manufacturing of the vaccine. The company had stopped manufacturing of Covishield in December 2021. On Covovax which has been approved as a booster dose for 18-years and above, he said, "We have six million doses ready but the demand is exactly zero." Covovax booster is now on the CoWin app, he said.

SII seeks inclusion of Covovax on CoWIN as heterologous dose for adults

Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union health ministry seeking the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. The letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) on March 27, they said. Last month, COVID-19 Working Group headed by Dr N K Arora had also recommended to the health ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults who have been vaccinated with two doses of either Covishield or Covaxin. The Drugs Controller General of India (DCGI) had on January 16 approved the market authorisation for Covovax for those who have been administered two doses of either Covishield or Covaxin. Also, Covovax has been approved by the World Health Organisation (WHO) and the US Food and Drug Administration (USFDA). The DCGI had approved Covovax for restricted use in ...

Wockhardt plans to roll out two vaccines from UK plant in a year

Drug firm Wockhardt plans to roll out two vaccines within a year from its UK-based facility as part of a tie-up with Serum Institute of India, a top company official said. Last year, a Wockhardt unit tied up with a subsidiary of Serum Institute of India to set up a vaccine manufacturing facility in Wrexham, North Wales (UK). "Serum has identified two vaccines and we plan to manufacture these products within the next 12 months after exhibit batches and regulatory approval is received," Wockhardt Managing Director and Global CEO Murtaza Khorakiwala said in an analyst call. Elaborating on the tie-up, he noted that the company has already concluded an agreement with Serum and as a result of that Wockhardt has received 10 million pounds as a contribution for reserving the manufacturing facility for 150 million doses per year of vaccine for 15 years. "This is 150 million doses per year for about a 15-year agreement. And in addition to a contract manufacturing, there is a joint venture ..

Multilateral bodies must join hands to deal with future outbreaks: SII CEO

Vaccine maker Serum Institute of India CEO Adar Poonawalla has called for global harmonisation or regulatory standards and said that cooperation among multilateral organisations is a must for dealing with future outbreaks. Speaking during the World Economic Forum Annual Meeting 2023, he said he is optimistic about the cooperation. As several leaders here warned against any complacency on the Covid front, Poonawalla said, "We need to keep educating people and dispel vaccine hesitancy". Serum Institute of India (SII) emerged as one of the largest vaccine makers in the world during the pandemic. Poonawalla pitched for advancing vaccine equity and global harmonisation of regulatory standards to allow vaccine manufacturers to make a better real-time impact. "Today, we go through a WHO approval process, you don't want every individual country asking for their own process and clinical trials. We have to be able to accept one level of standard," he added. Poonawalla said he is hopeful th

SII seeks inclusion of Covovax in CoWIN portal as booster dose for adults

Covovax is manufactured through technology transfer from Novavax

Covid-19: Serum's Covovax gets the nod as a mix-and-match booster shot

Experts say no current vaccine protects against sub-lineages of Omicron

SII's Covid vaccine Covovax gets heterologous booster dose approval

Covovax can now be used as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin

SII's free Covishield supply to govt: First 8 mn doses set for dispatch

Amid a rise in Covid cases in some countries, Serum Institute of India has started supply of Covishield to the Centre free of cost with the first lot of 80 lakh doses set to be dispatched from Saturday, official sources said. Since the launch of the anti-Covid vaccination drive, SII has so far provided 170 crore doses of Covishield to the government. According to an official source, Prakash Kumar Singh, Director Government and Regulatory Affairs at Serum Institute of India, had written to Union Health Ministry mentioning that the Pune-based firm will provide two crore doses of Covishield vaccine worth Rs 410 crore to the Government of India free of cost. The Health Ministry has issued a consignee list for the supply of 80 lakh doses of Covishield which will be supplied by the company Saturday, an official source said.

Covid-19 situation in India better than elsewhere: SII CEO Adar Poonawalla

Serum Institute of India CEO Adar Poonawalla on Sunday lauded India's fight against the Covid pandemic, saying the government and the healthcare workers contributed largely to tackling the pandemic

Poonawalla gets Patangrao Kadam award, Maha Dy CM hails SII for vaccine

Maharashtra Deputy Chief Minister Devendra Fadnavis on Sunday lauded vaccine manufacturer Serum Institute of India and its CEO Adar Poonwalla for their contribution in the fight against COVID-19. He was speaking at the inauguration of Bharti Super Specialty Hospital at Bharti Vidyapeeth where Poonwalla was conferred with the first Dr Patangrao Kadam Memorial Award. "I am very happy we got the opportunity to felicitate Poonawalla. It is an opportunity to say thanks for saving us. The entire nation wants to thank you," he said. The vaccines provided by SII during the pandemic showed the country's strength to the world, Fadnavis said. He also hailed the Bharti Vidyapeeth and said Patangrao Kadam was a leader who created 190 institutes to provide quality education and created quality human resource. ' The event was also attended by Nationalist Congress Party chief Sharad Pawar and Himachal Pradesh CM Sukhvinder Singh Sukhu. Adar Poonawalla was carrying forward the legacy of his fath

Covovax to get approval as booster in 10-15 days, says SII CEO Poonawalla

Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus. Speaking to reporters on the sidelines of an event at Bharti Vidyapeeth University here, Poonawalla, when asked about states and districts not getting Covishield vaccines, said there are ample stocks with the Union government for supply. "Covovax will be approved as a booster in the next 10-15 days. It is actually the best booster because it works very well against Omicron, more than Covishield," said Poonawalla. He said everyone was looking at India, not just in terms of healthcare but because the country managed to take care of a huge and diverse population and also helped 70 to 80 nations during the COVID-19 pandemic. "This was all possible because of the leadership of our Central government, our state governments, healthcare workers, manufacturers, all of who